(RTTNews) -  Monday, Orexigen Therapeutics Inc. (OREX: News ) appointed Dawn Viveash as Head of Global Regulatory Affairs. Viveash will oversee the U.S. and international regulatory affairs activities including regulatory filings for Contrave and Empatic. With over 20 years of experience in the biopharmaceutical industry, Viveash has experience with all stages of development and product commercialization. Viveash was most recently at Amylin Pharmaceuticals as Vice President of Regulatory Affairs and Safety

The company also appointed Suzanne McDonald as Head of Managed Markets and Government Affairs, Preston Klassen as Head of Global Contrave Program and Whedy Wang as Head of Global Biomedical Information. The new hires will strengthen the company's efforts with global health authorities, payers and policy makers and tremendously support the filing of the Contrave New Drug Application with the FDA which remains on track for the first half of 2010, the company noted.
Orexigen Therapeutics Inc., a biopharmaceutical company, focusing on the development of pharmaceutical product candidates for the treatment of obesity.

Click here to receive FREE breaking news email alerts for OREXIGEN THERAPEUTICS and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com